Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-016948
Filing Date
2023-05-15
Accepted
2023-05-15 08:30:29
Documents
33
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 310083
2 ex31-1.htm EX-31.1 20333
3 ex31-2.htm EX-31.2 14861
4 ex32-1.htm EX-32.1 6784
5 ex32-2.htm EX-32.2 6735
  Complete submission text file 0001493152-23-016948.txt   1538417

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE npls-20230331.xsd EX-101.SCH 11065
7 XBRL CALCULATION FILE npls-20230331_cal.xml EX-101.CAL 19705
8 XBRL DEFINITION FILE npls-20230331_def.xml EX-101.DEF 21472
9 XBRL LABEL FILE npls-20230331_lab.xml EX-101.LAB 103698
10 XBRL PRESENTATION FILE npls-20230331_pre.xml EX-101.PRE 77235
27 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 145793
Mailing Address 4125 BLACKHAWK PLAZA CIRCLE SUITE 166 DANVILLE CA 94506
Business Address 4125 BLACKHAWK PLAZA CIRCLE SUITE 166 DANVILLE CA 94506 (925)-362-3169
NP Life Sciences Health Industry Group Inc. (Filer) CIK: 0001781726 (see all company filings)

EIN.: 832912878 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-56140 | Film No.: 23918611
SIC: 8200 Services-Educational Services